11,753 Shares in Haleon plc (NYSE:HLN) Bought by Fiduciary Alliance LLC

Fiduciary Alliance LLC bought a new position in shares of Haleon plc (NYSE:HLN) in the 4th quarter, Holdings Channel.com reports. The fund bought 11,753 shares of the company’s stock, valued at approximately $112,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Baker Tilly Wealth Management LLC lifted its holdings in Haleon by 13.6% during the 4th quarter. Baker Tilly Wealth Management LLC now owns 67,384 shares of the company’s stock worth $643,000 after buying an additional 8,079 shares during the last quarter. Douglas Lane & Associates LLC lifted its holdings in Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after buying an additional 161,865 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Haleon by 41.3% during the 4th quarter. GAMMA Investing LLC now owns 21,258 shares of the company’s stock worth $203,000 after buying an additional 6,215 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after buying an additional 1,026,939 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Up 1.2 %

Haleon stock opened at $9.12 on Thursday. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The company has a market capitalization of $41.28 billion, a P/E ratio of 26.82, a PEG ratio of 2.95 and a beta of 0.29. The stock has a 50-day simple moving average of $9.57 and a 200-day simple moving average of $9.70.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of recent analyst reports. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.